Navigation Links
Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study

ROCHESTER, Minn. -- A new Mayo Clinic study due to be presented at the annual meeting of the American Society of Human Genetics in San Diego this week shows that a chromosome test called FISH is better than conventional methods in identifying chromosomal genetic abnormalities associated with plasma cell malignancies. This improved chromosomal analysis may help physicians better assess a patients prognosis and likelihood to respond to a given treatment.

Plasma cell proliferative disorders, or PCPD, account for approximately 10 percent of all blood born cancers that range from the very slow-growing smoldering myeloma to a very aggressive plasma cell leukemia.

The study will be presented by Ryan Knudson of the Mayo Clinic Cytogenetics Laboratory at 6:30 p.m., CDT, Wednesday, Oct. 24.

FISH, which stands for fluorescence in situ hybridization, detected chromosomal abnormalities in 67 percent of 1,548 patients with suspected PCPD. Conventional chromosomal analysis detected abnormalities in only 10 percent of the same patients. The FISH test is designed to detect genetic abnormalities in plasma cells whereas other conventional methods typically looks within any cell type that is present, says the lead author of the study, Rhett Ketterling, M.D., a Mayo Clinic pathologist and geneticist who specializes in chromosomes and chromosomal abnormalities.

This test is a marked improvement over conventional chromosomal analysis and has become readily accepted into the diagnostic algorithm in patients with PCPD at Mayo Clinic and at other leading academic institutions, Dr. Ketterling says.

The test should be applied to patients diagnosed with PCPD, particularly multiple myeloma, to determine the presence of genetic abnormalities that could offer insight into prognosis, he states.

Our results show that a targeted plasma-cell specific FISH analysis is an important method for detecting common genetic abnormalities typically seen in patients with multiple myeloma, Dr. Ketterling says.


Contact: Amy Reyes
Mayo Clinic

Related medicine news :

1. WHO Gives Its Approval For Bird Flu Test Kit
2. Microchip gives blind a chance of sight
3. Microchip gives blind a chance of sight
4. Combined scan gives exact cancer diagnosis
5. Tennis gives protection against heart disease lifelong
6. Camera gives hope for detection of breast cancer
7. Pancreas transplant gives hope to type 2 diabetes
8. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
9. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
10. FDA gives “black box warning” against three asthma drus
11. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Calif. , Dec. 1, 2015 ... products and services, announced today that it has been ... services organization. Members served by Novation will have access ... devices, sports bracing products and soft goods dedicated to ... --> The aging U.S. population, rising prevalence ...
(Date:12/1/2015)... 2015 Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country of ... registered in Europe in 2015 were tested in ... Russia has always been a country of choice for ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: